Which is the Biggest Pharmaceutical Company in India?

Sun Pharmaceutical Industries Limited, commonly known as Sun Pharma, is the largest pharmaceutical company in India. Headquartered in Mumbai, it supplies medicines to more than 100 countries and plays a major role in the global healthcare industry. The company is especially known for its strong presence in both generic and specialty medicines.

How Sun Pharma Became India’s Largest Pharma Company?

Sun Pharma started its journey in 1983 when Dilip Shanghvi began the company with just a few psychiatry medicines and a very small team. Over time, the company expanded rapidly by improving its product range and entering new markets.

A major turning point came in 2014 when Sun Pharma acquired Ranbaxy Laboratories. This deal made Sun Pharma one of the largest specialty generic pharmaceutical companies in the world.

Global Presence and Business Reach

Sun Pharma earns a large part of its income from international markets. Around 70% of its revenue comes from outside India. The United States and India are its biggest markets, contributing more than half of the company’s total earnings.

The company has manufacturing units in many regions, including India, the US, Europe, Asia, Africa, and Australia. This wide network helps Sun Pharma supply medicines across the globe efficiently.

Wide Range of Medicines

Sun Pharma produces medicines for many different health problems. These include treatments for heart diseases, diabetes, infections, mental health issues, skin conditions and cancer.

The company also manufacture Active Pharmaceutical Ingredients (APIs), which are the key components used to make medicines. Some of its well-known drug ingredients include baricitinib, brivaracetam, and dapagliflozin.

Important Acquisitions and Growth Strategy

Sun Pharma has grown by acquiring many companies over the years. Some important acquisitions include:

• Taro Pharmaceuticals (a major dermatology company)
• DUSA Pharmaceuticals (focused on dermatology devices)
• URL Pharma’s generics business
• Pharmalucence (to strengthen US manufacturing)
• Pola Pharma in Japan
• Concert Pharmaceuticals in the US

These acquisitions helped Sun Pharma expand into new markets and improve its product portfolio.

Focus on Innovation and Research

Sun Pharma also invests in research and development through its separate company, Sun Pharma Advanced Research Company (SPARC). This division works on developing new medicines and improving drug delivery systems.

Recent Developments

In recent years, Sun Pharma has continued to grow by entering new partnerships and acquisitions. In 2024, it moved to fully acquire Taro Pharmaceuticals, and in 2025, it expanded further by acquiring Checkpoint Therapeutics, strengthening its position in cancer treatment.